Piramal Pharma

Piramal Pharma Ltd announced that the US Food and Drug Administration has issued an Establishment Inspection Report for its manufacturing facility in Sellersville, United States, and the inspection has been successfully closed. The company had previously intimated the exchanges about the inspection on May 10, 2026. The Sellersville facility is a key site for the company's contract development and manufacturing operations serving the North American market. With the issuance of the EIR, the facility now stands cleared of any regulatory observations, ensuring uninterrupted production and supply commitments.

Powered by Tijori

June 3 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA - RECEIVES PERMANENT REVOCATION OF CLOSURE ORDER FOR DAHEJ SITE

• PIRAMAL PHARMA LTD- OPERATIONS AT DAHEJ SITE CONTINUE TO BE IN NORMAL COURSE

Source text: ID:nBSE5pky1H

Further company coverage: PIRM.NS

(([email protected];))

May 18 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA LTD - ANNOUNCES SUCCESSFUL CLOSURE OF US FDA INSPECTION AT DIGWAL FACILITY

• PIRAMAL PHARMA LTD - US FDA ISSUES ESTABLISHMENT INSPECTION REPORT

Source text: ID:nBSEnYRM5

Further company coverage: PIRM.NS

(([email protected];))

By Kashish Tandon

April 29 (Reuters) - India's Piramal Pharma PIRM.NS hopes to accelerate earnings growth over the next two to three years, led by rising demand for complex drugs, including targeted cancer therapies, a top executive said on Wednesday.

The company, which sells popular medicines like the emergency contraceptive tablet i-pill and lacto calamine lotion in India, relies on contract drug manufacturing for 55% of its overall revenue.

Global biotech funding into Indian contract drug makers is improving after a year of slowdown marked by macroeconomic and geopolitical uncertainty. Indian drugmakers also stand to gain from U.S. curbs on biotech funding for rival Chinese firms.

"Biotech funding in the second half of the year was about 80% higher than in the second half of last year, and that is now translating into higher requests for proposals and order inflows," Nandini Piramal, chairperson of Piramal Pharma, told Reuters, attributing the funding pick-up to lower interest rates and reduced uncertainty in the U.S. pharma sector.

The company expects to clock early-to-mid-teens revenue growth in two to three years, the chairperson said, after reporting a 3% drop in fiscal 2026 revenue, hurt by a 10% slump in its contract drug manufacturing, its biggest vertical. The revenue loss caused margins to shrink to 13% from 17%.

Within contract manufacturing, Piramal is prioritising higher-value segments.

Global demand has been rising for antibody-drug conjugates (ADCs), which are targeted cancer therapies that link chemotherapy drugs to antibodies, as drugmakers expand oncology pipelines.

"We've added a significant number of customers, both big pharma and biotech, as this sector (CDMO) has grown," Piramal said.

What is not moving up the priority ladder for the company are the active ingredients for weight-loss drugs, generic semaglutides, given the intense competition and falling prices in the market, she said.

"These (ADCs) are high fixed-cost businesses, and as revenues grow, operating leverage flows through to the bottom line."

($1 = 94.8375 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]; 8800437922;))

April 13 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• CLOSURE OF US FDA INSPECTION AT MANUFACTURING FACILITY AT LEXINGTON

• US FDA HAS ISSUED EIR FOR SAID MANUFACTURING FACILITY WITH VAI

Source text: ID:nBSEbbHpn

Further company coverage: PIRM.NS

(([email protected];;))

Feb 11 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• GPCB IMPOSED INTERIM ENVIRONMENTAL DAMAGE COMPENSATION OF 10 MILLION RUPEES

Source text: ID:nNSE7Tj04V

Further company coverage: PIRM.NS

(([email protected];))

** HDFC Securities starts coverage on Indian contract drug makers Divi's Laboratories DIVI.NS, Anthem Biosciences ANTH.NS, Sai Life Sciences SAIE.NS, Laurus Labs LAUL.NS and Piramal Pharma PIRM.NS

** Brokerage sees rising R&D outsourcing boosting Indian contract drug makers that have expanded capabilities to cover various stages of drug development

** India's share in global contract research, development, and manufacturing organisations (CRDMO) market to rise to 4.7% by 2029 from 3.8% in 2024, "making it an attractive sector" - HDFC

** adds, low labour costs advantage as companies reduce China dependence

** Expects revenue CAGR to accelerate to 15% in FY25-28 vs 9% in FY23-25; EBITDA CAGR seen at 22% vs 12%

** The table below lists HDFC's rating and PT on its CRDMO picks

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Dec 11 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• US FDA ISSUED A FORM-483, WITH FOUR OBSERVATIONS

• US FDA CONDUCTED INSPECTION OF LEXINGTON (KENTUCKY, USA) FACILITY

Source text: ID:nBSE4pQ0vP

Further company coverage: PIRM.NS

(([email protected];))

Aug 21 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA LTD - CO, NEWAMSTERDAM PHARMA INVEST TO ENHANCE ORAL SOLID DOSAGE CAPABILITIES

• PIRAMAL PHARMA LTD - INVESTMENT EXPECTED TO CREATE MORE THAN 20 NEW JOBS AT SELLERSVILLE SITE

Source text: ID:nBSEbp5P1k

Further company coverage: PIRM.NS

(([email protected];;))

Aug 7 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• REPORTS FIRE AT THIRD-PARTY WAREHOUSE IN TELANGANA

• FIRE UNDER CONTROL, CAUSE UNDER INVESTIGATION

• INVENTORY AFFECTED ESTIMATED AT 450 MILLION RUPEES, COVERED BY INSURANCE

Source text: ID:nNSE9RzkVc

Further company coverage: PIRM.NS

(([email protected];;))

July 22 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• BOARD APPROVES SALE OF UNIT FOR 85 MILLION RUPEES

• UNIT DECOMMISSIONED, CONTRIBUTED NIL TO TURNOVER

Source text: ID:nBSE4nC3jR

Further company coverage: PIRM.NS

(([email protected];;))

July 3 (Reuters) - Carlyle Group Inc CG.O:

• CARLYLE GROUP MAY SELL UP TO 10% STAKE IN INDIA'S PIRAMAL PHARMA VIA BLOCK DEALS - MONEYCONTROL

Source text: [ID:]

Further company coverage: CG.O

(([email protected];;))

** Shares of Piramal Pharma PIRM.NS rise about 2.5% to 222.29 rupees apiece after Goldman Sachs starts coverage with "buy" rating

** PIRM shares are down 5.7% in the last two sessions amid a broader market drop after the U.S. announced reciprocal tariffs

** Goldman Sachs sets a target price for PIRM at 275 rupees, implying a potential upside of 26.8% in the next 12 months

** PIRM is well-placed to deliver a top-quartile profit growth over the fiscal years 2024-2028, says Goldman Sachs

** Forecasts PIRM to post sustainable growth in contract development and manufacturing segment, capacity ramp-ups, and domestic consumer healthcare businesses

** PIRM shares are down 18.5% in 2025 so far mirroring the small-cap index .NIFSMCP100 of which it is a constituent

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Piramal Pharma PIRM.NS rise 2.5% to 227 rupees apiece

** Pharma company's unit gets market authorization from UK's drug regulator for the use of its drug formulation to treat hypotension in neonates, infants and children

** With this, PIRM has secured commercialization rights for the drug Neoatricon for the European Union, the UK and Norway

** PIRM is down 15% in 2025 compared to a 14% fall in the small-cap 100 index .NIFSMCP100, of which it is a constituent

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

March 20 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA LTD- PIRAMAL CRITICAL CARE AND BREPCO ANNOUNCES MHRA APPROVAL FOR NEOATRICO IN UK

Source text: ID:nBSE3WJl3

Further company coverage: PIRM.NS

(([email protected];;))

Adds details from exchange filing, background from paragraph 2

Feb 28 (Reuters) - India's Piramal Enterprises PIRA.NS said in an exchange filing on Friday that it had received a tax demand of 15.02 billion rupees (nearly $172 million) for the sale of its pharmaceutical business to Piramal Pharma PIRM.NS in fiscal year 2021.

A tax office in the state of Maharashtra has asked the financial services company to pay 18% Goods and Services Tax (GST) on the deal, the latter said in the filing.

The tax bill amounts to about 15% of its revenue for the fiscal year ended March 31, 2024. Piramal Enterprises said it has solid grounds to challenge the "unjustified" demand.

The company sold its pharmaceutical business and other related units to Piramal Pharma PIRM.NS for 44.87 billion rupees in October 2020.

Maharashtra's tax office has contended that the transfer of its pharma business to Piramal Pharma counts as an itemized sale and not a slump sale, the company said.

A slump sale, which receives more preferential tax treatment, refers to the sale of all assets and liabilities of an undertaking without values being assigned to individual assets and liabilities. Such a sale must also not hinder the business operations of the transferred entity.

An itemized sale, on the other hand, refers to assets and liabilities being sold with separate values assigned to each item.

Piramal Enterprises said it expects that the order would be set aside.

($1 = 87.3660 Indian rupees)

(Reporting by Ananta Agarwal in Bengaluru; Editing by Shilpi Majumdar and Pooja Desai)

(([email protected];))

Corrects paragraph 14 to say India has "committed" not "invested" $2.86 billion

By Rishika Sadam, Kashish Tandon and Bhanvi Satija

HYDERABAD Feb 27 (Reuters) - India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw material imports at a time when many global pharmaceutical firms are counting on the nation to reduce their reliance on China.

India's Contract Research Development and Manufacturing Organisation (CRDMO) sector is at an inflection point, with the potential to grow seven-fold to $22 billion-$25 billion by 2035, according to a report by Boston Consulting Group.

Globally, the market stands at $140 billion-$145 billion.

"The government has to understand that this industry has potential, if not scale, right now," Krishna Kanumuri, CEO and managing director at Sai Life Sciences SAIE.NS, said at an event earlier this week.

India's contract drug manufacturers have gained from global companies' efforts to diversify their supply chain after the pandemic and a U.S. bill that would prohibit federal contracts with certain Chinese biotech firms on national security grounds.

However, India's policies are yet to play catch-up.

For instance, prolonged approval times and regulatory demands tied to certain raw material imports meant Indian firms often require eight to 15 days to initiate projects, while their Chinese peers could do it within three days, according to Vikash Aggarwala, MD and Partner at BCG's healthcare practice.

Industry insiders pushed for more business-friendly policies in the world's fifth-largest economy, which is heavily dependent on China for drug-related raw materials.

Piramal Pharma's PIRM.NS Chairperson Nandini Piramal lamented the lack of customs warehouses at the right locations and related logistics costs, a dearth of cold storage units, and delays tied to the clearance of certain raw material imports.

"All of those, I think, add more friction to the ease of doing business," Piramal told Reuters.

Some others highlighted the delay in approvals due to the lack of a centralized, digital, single-window clearance system.

Syngene's SYNN.NS CEO-designate Peter Bains said the "friction and delay" could be compressed, highlighting it was "a disadvantage that India has against other jurisdictions".

India's health and finance ministries did not respond to Reuters requests seeking comment.

The country, which offers cheap labour and a large talent pool, has already committed over $2.86 billion in the local biotech industry, according to the BCG report. But industry insiders are urging for more.

"I would really pitch for a CRDMO park... with policies where you don't have to go and get permissions from the local drug controller for making changes, where there are easy export and import capabilities," Aragen Life Sciences CEO Manni Kantipudi said.

($1 = 87.3900 Indian rupees)

(Reporting by Rishika Sadam, Kashish Tandon and Bhanvi Satija; Editing by Dhanya Skariachan and Janane Venkatraman)

(([email protected]; 8800437922;))

By Kashish Tandon, Bhanvi Satija and Rishika Sadam

HYDERABAD Feb 26 (Reuters) - The rising adoption of artificial intelligence in the pharmaceutical industry dominated discussions at a conference in India this week, while executives largely preferred to wait for more clarity on U.S. President Donald Trump's tariff threats.

Drugmakers such as Amgen AMGN.O and contract manufacturers including Parexel highlighted AI's role in reducing the time taken to conduct certain parts of the trials.

U.S.-based Parexel said it was piloting an AI model to generate drug safety reports 30-45 minutes faster than the manual process. The AI-generated reports are then verified by an expert.

AI can help halve the cost and time taken to develop a drug, from discovery through commercial production, compared to the traditional process, said Chaitanya Royyuru, partner at consulting firm EY. Royyuru estimated that the process currently takes more than 10 years and costs about $1 billion.

Discovering new molecules and drug repurposing, or using a drug for a condition outside of its approved indication, are other areas where AI is being utilized, executives said.

Beyond drug discovery processes, AI is also being used in medical image reading, where it is able to assist doctors in finding anomalies.

"Sometimes, when we look at an X-ray and we think it's normal, but AI says look, there's a small cancer you're missing," said Nageshwar Reddy, chairman, Asian Institute of Gastroenterology.

"And when we actually look at it very carefully and follow the patient, there's a cancer coming there," Reddy said.

Ken Washington, chief technological officer, Medtronic, said, "The bottom line is that AI has to be everybody's job."

WAIT AND WATCH ON TARIFFS

Trump's plans to levy tariffs on pharmaceutical imports had cast a shadow over the two-day conference as India is among the top exporters to the U.S., especially of cheaper versions of popular drugs.

However, drugmakers including Dr Reddy's REDY.NS said they were still waiting for clarity on the tariffs.

"Right now, it's wait and watch. There is no clarity on what the tariffs are, if any, or if there is a transition period," said Nandini Piramal, chairperson at Piramal Pharma, which provides contract manufacturing and development services.

(Reporting by Kashish Tandon, Bhanvi Satija and Rishika Sadam in Hyderabad; Editing by Sriraj Kalluvila)

(([email protected]; Outside U.S. +91 9873062788;))

Adds comments from Piramal Pharma executive in paragraphs 7 and 8

By Rishika Sadam

HYDERABAD, Feb 25 (Reuters) - Indian drugmakers are likely to remain competitive in the generics market even as U.S. President Donald Trump's plans to levy tariffs on pharmaceutical imports, Dr Reddy's Managing Director GV Prasad said on Tuesday.

Trump has said he could impose duties of 25% or more on pharmaceutical imports and an announcement could be made by next month. The U.S. accounts for nearly a third of India's pharma exports, mainly cheaper versions of popular drugs, with sales jumping 16% to about $9 billion last fiscal year.

The industry is still waiting for more clarity before taking any action, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana.

"In reality, to shift (the manufacturing of) all these products into the United States is not practical. They don't have that much capacity, and their costs will rise. Even with tariffs, I think Indian and Chinese companies would be competitive."

The tariffs would likely raise the costs for U.S. consumers or middlemen, he said.

Nandini Piramal, chairperson at Piramal Pharma, which provides contract manufacturing and development services, echoed Prasad's comments on the lack of clarity.

"For us, our strategy is to be geography agnostic. If companies want to pay higher prices in the U.S. to make in the U.S., we're very happy to help them do so."

India's drug industry has pinned its hopes on bilateral talks to earn an exception, though Trump has ruled out any such concession so far.

(Reporting by Rishika Sadam in Hyderabad; Writing by Manas Mishra; Editing by Janane Venkatraman and Sriraj Kalluvila )

(([email protected]; www.twitter.com/Manaswrites15;))

Feb 18 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• US FDA INSPECTION AT PIRAMAL PHARMA'S FACILITY LOCATED AT TURBHE

• ON CONCLUSION OF INSPECTION, A FORM-483 WAS ISSUED WITH 6 OBSERVATIONS

Source text: ID:nBSE410CGn

Further company coverage: PIRM.NS

(([email protected];;))

Jan 28 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA DEC-QUARTER CONSOL NET PROFIT 36.8 MILLION RUPEES

• PIRAMAL PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 22.04 BILLION RUPEES

Source text: ID:nNSE9J9WMD

Further company coverage: PIRM.NS

(([email protected];;))

Jan 27 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• GETS GST ORDER WITH PENALTY OF 154.4 MILLION RUPEES

Further company coverage: PIRM.NS

(([email protected];;))

Jan 22 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• DIVISION ANNOUNCES US LAUNCH OF CHLORPROMAZINE HYDROCHLORIDE FOR INJECTION

Source text: ID:nBSE151Czh

Further company coverage: PIRM.NS

(([email protected];;))

** Shares of Piramal Pharma PIRM.NS rise 5.1% to 264.05 rupees

** JM Financial Institutional Securities starts coverage with a "buy" and TP of 340 rupees, a Street-high, per data compiled by LSEG

** TP at 35% premium to stock's previous close

** PIRM's differentiated offerings, global manufacturing presence and end-to-end capabilities will help to capitalise on the ongoing contract drug manufacturing industry expansion - note

** Brokerage sees margin expansion on increasing contribution from on-patent manufacturing

** PIRM stock up ~91% YTD vs 24% gains in 2023

(Reporting by Vijay Malkar)

(([email protected];))

Dec 6 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA SOLUTIONS INC AND VETDC, INC ENTERED INTO SETTLEMENT AGREEMENT

• SETTLEMENT AGREEMENT FOR USD 407,400

Source text: ID:nBSE7TgCfd

Further company coverage: PIRM.NS

(([email protected];;))

** Shares of Piramal Pharma PIRM.NS rise 6.5% to 233 rupees

** Co posted a near five-fold surge in Q2 consol net profit to 225.9 mln rupees (~$3 million)

** Revenue in core contract development and manufacturing organisation segment jumps 24%

** More than 12 mln shares change hands, 1.5x its 30-day avg

** Five analysts covering the stock on avg have a "buy" rating; median PT is 260 rupees - LSEG data

** Stock up 68% so far this year

($1 = 84.0650 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Sept 30 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA SOLUTIONS ANNOUNCES $80M EXPANSION PLAN

• EXPANSION PLAN FOR STERILE INJECTABLES FACILITY IN LEXINGTON, KENTUCKY

Source text for Eikon: ID:nBSE2rfhlN

Further company coverage: PIRM.NS

(([email protected];;))

** Shares of Piramal Pharma PIRM.NS up 5% to 228.6 rupees, its biggest one-day gain in more than 2 weeks

** Co's contract manufacturing division's turnaround is progressing well, hospital generics business should be back to growth from 2HFY25, Jefferies says

** Raises TP to 260 rupees from 195 rupees; maintains 'Buy' rating

** Co aims to grow revenue to over $2 bln with 25% EBITDA margin by FY2030

** This implies rev/EBITDA CAGRs of 12.2%/20.3%, which is achievable - Jefferies

** Raises FY25/26 EBIDTA estimates by 4-10% on better contract manufacturing margins

** Analysts' avg rating on stock is "Buy" (with median TP 245 rupees) vs "Hold" for peer IPCA Laboratories IPCA.NS (with median TP 1,350 rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Sept 17 (Reuters) - Piramal Pharma Ltd PIRM.NS:

• PIRAMAL PHARMA - RECEIVED SBTI APPROVAL FOR COMMITMENT TO REDUCE SCOPE 1 AND 2 GHG EMISSIONS BY 42% AND SCOPE 3 BY 25% BY FY 2030

Source text for Eikon: ID:nBSEccwrM7

Further company coverage: PIRM.NS

(([email protected];))

** Shares of Piramal Pharma PIRM.NS jump 12% to record high of 216.58 rupees

** More than 2.1 mln shares changed hands in five block deals at 195.32-209.80 rupees each -LSEG data

** Prices at a premium to last close price of 193.10 rupees

** Stock last up ~11%, set for its best day ever

** Trading vol of 52 mln shares is 9.5x the 30-day avg

** Stock is up 53% YTD

(Reporting by Nishit Navin)

(([email protected];))